FDA Inspection 1042533 — Braeburn Pharmaceuticals Inc.
The FDA completed an inspection of Braeburn Pharmaceuticals Inc. on Feb 8, 2018 in Princeton, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 2 citations were issued during this inspection. Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Feb 8, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Princeton, NJ (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)
Citations
| ID | CFR | Description |
|---|---|---|
| 21360 | FDCA 505-1(f)(4) | Failure to comply with REMS Implementation System |
| 6732 | 21 CFR 314.80(c)(1)(i) | Late submission of 15-day report |